{"organizations": [], "uuid": "33574c6e3db5e4b864f0bcae5013c56b757bedd2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180509.html", "section_title": "Archive News &amp; Video for Wednesday, 09 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-lodo-therapeutics-has-formed-a-str/brief-lodo-therapeutics-has-formed-a-strategic-drug-discovery-collaboration-with-genentech-idUSFWN1SG168", "country": "US", "domain_rank": 408, "title": "BRIEF-Lodo Therapeutics - Has Formed A Strategic Drug Discovery Collaboration With Genentech", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-09T20:12:00.000+03:00", "replies_count": 0, "uuid": "33574c6e3db5e4b864f0bcae5013c56b757bedd2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-lodo-therapeutics-has-formed-a-str/brief-lodo-therapeutics-has-formed-a-strategic-drug-discovery-collaboration-with-genentech-idUSFWN1SG168", "ord_in_thread": 0, "title": "BRIEF-Lodo Therapeutics - Has Formed A Strategic Drug Discovery Collaboration With Genentech", "locations": [], "entities": {"persons": [{"name": "coll", "sentiment": "negative"}], "locations": [{"name": "lodo", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "genentech", "sentiment": "negative"}, {"name": "lodo therapeutics", "sentiment": "negative"}, {"name": "roche holding ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - Roche Holding AG:\n* LODO THERAPEUTICS - HAS FORMED A STRATEGIC DRUG DISCOVERY COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP\n* LODO THERAPEUTICS - UNDER AGREEMENT, GENENTECH WILL UTILIZE COâ€™S PROPRIETARY GENOME MINING AND BIOSYNTHETIC CLUSTER ASSEMBLY PLATFORM\n* LODO THERAPEUTICS - WILL RECEIVE UNDISCLOSED UPFRONT PAYMENT, ELIGIBLE TO RECEIVE MILESTONE PAYMENTS UP TO $969 MILLION FROM DEAL\n* LODO THERAPEUTICS - IS ELIGIBLE TO RECEIVE TIERED-ROYALTIES ON SALES OF CERTAIN PRODUCTS RESULTING FROM COLLABORATION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T20:12:00.000+03:00", "crawled": "2018-05-10T17:28:27.013+03:00", "highlightTitle": ""}